Oncolytics Biotech Inc T.ONC

Price does matter

[inthno]

On October 7th 2024 we closed at 1.91

Today December 5th 2024 we are at 1.24

Stock markets at all time highs so what is our excuse.

Yes all we have to do now is wait for the next set of results I am sure or a partnership or bo or the worst bought deal with warrants attached.

A consolidation or reverse split will not happen and means nothing anyway as nasdaq has done zip for the company.

Thank heavens according to cf we had a leading health care provider on the last financing and also that Mc exercised 350k options and been saying a business development deal or partnership since the mice and CarT.

Eventually.someone might get it right.

[Noteable]

"so what is our excuse" - Canaccord.

[Noteable]

Ranking of financial advisors for COVID-19-related deals in the pharmaceutical industry, 9M 2024 Table with 3 columns and 5 rows. Advisor Q1 2024 rank Q1 2023 rank Cantor Fitzgerald 1 - Citigroup

[Noteable]

October 25, 2024 - Cantor Fitzgerald analyst Louise Chen maintained a "Overwight" Buy rating on Pfizer (PFE )–

[inthno]

Don't care about Pfizer as they ki da screwed us imo as the bracelet was supposed to be an extension of mbc 213 and aware1 and somehow the company either completely screwed up or got talked into using avalumab instead of atizalamab which was working aware 1. They even said in the post conference that it was an expected result so.why even do that part of the trial knowing that. Then Pfizer

[inthno]

I think a lot of people are upset as the way things have gone and been handled. This is from paradigm captital which followed us back in 2011.   Now we have a price target of 5 dollars by most analysts which is less than the closing price back in 2011 and everyone seems to think that this is ok with all the advancements and consolidation since then. Company Profile Sector Healthcare

[inthno]

From the August 24th 2015 presentation. Look at how many patents we had and notice the number of patients that were treated about 10 years ago , 1100 and 10 years later they say they have treated the same number of patients. 3 Oncolytics Overview Conducted 30+ clinical studies in 13 indications 400+ issued patents and 235 pending applications worldwide 1,100+ patients treated; strong safety

[Normandt]

We are more upset by your constant negativity, your multiple usernames, and the game you play saying everything and the opposite depending on the group or the person you talk with (do you remember dreamer and your teamates or dreamer replying to himself with a different username). We all know how hyppocrit you are and what you are capable of to bash your own investment and the people who

[Noteable]

With Cantor Fitzgerald's analyst Louise Chen's "Overweight" Buy rating on Pfizer (PFE  and her recent addition of ONCY to her coverage of biotech companies, ONCY appears to be 'prime' partnership material for Pfizer's ADC, CDK4/6, PARP-1 inhibitor and PD-L1 immune checkpoint inhibitors of I/O and small molecule pipeline of priducts, which ONCY has demonstrated as

[Noteable]

" For Pfizer, the reworking of its Merck KGaA partnership [came] as it is [was]  attempting to buy cancer drugmaker Seagen in one of the pharmaceutical industry’s largest acquisitions of recent years. As one of Seagen’s drugs is also used to treat bladder cancer, analysts [had] speculated Pfizer might divest its interest in Bavencio to head off any antitrust challenges to the deal."